CBU
NTLA icon

CIBC Bancorp USA’s Intellia Therapeutics NTLA Stock Holding History

CIBC Bancorp USA’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$183K Buy
+10,585
New +$130K ﹤0.01% 1280

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
CGH
Contrarius Group Holdings Hamilton, Bermuda $1.77B AUM 83.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

CIBC Bancorp USA's NTLA Position: Q3 2025 in Review

CIBC Bancorp USA opened a new position in Intellia Therapeutics (NTLA) in Q3 2025: 10,585 shares worth $183K. The stake represents ﹤0.01% of the portfolio and ranks #1280 among its holdings.

282 funds tracked by Wall St. Rank hold NTLA as of Q3 2025.

  • CIBC Bancorp USA held 10,585 shares of Intellia Therapeutics worth $183K as of Q3 2025.
  • Intellia Therapeutics was a new CIBC Bancorp USA position in Q3 2025.
  • Intellia Therapeutics made up ﹤0.01% of CIBC Bancorp USA's portfolio in Q3 2025, its #1280 holding.
  • 282 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q3 2025.

Based on CIBC Bancorp USA's 13F filing for Q3 2025, filed 12 Nov 2025.